ABSTRACT
Ebola virus is a highly virulent pathogen causing severe hemorrhagic fever with a high fatality rate in humans. Although safe and effective therapeutics and treatment strategies or other medicinal agents in post-exposure therapeutics for the prevention of Ebola hemorrhagic are currently unavailable, a significant effort has been put forth to identify several promising candidates for post-exposure therapeutics and treatment of Ebola hemorrhagic fever. These potential strategies and novel technology include monoclonal antibody cocktail, polymerase inhibitors and lipid nanoparticle/small interfering RNA. This article summarizes recent advances in therapeutics and treatment strategies and novel technology in Ebola virus post-infection in small animals and non-human primates.